Should I buy IQVIA (IQV) stock or is it too late?

IQVIA · Health Care · price $262

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: BMO Capital — 73% of its targets hit on this sector (239 calls tested). It aims for $270 (+2.9 %), call made on July 30, 2026, maturing on July 30, 2027 (29 d ago).

The 7 reliable analysts $276+5.2 %

The 3 other firms $210-20 %

How to read it: the 7 reliable firms are not filtered by optimism — 5 aim above the price, 2 below, hence their $276 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on IQVIA

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Citigroup	80 %	+30.2 %	5	$200 -24%
Stifel	71 %	+28.7 %	7	$276 +5%
Baird	83 %	+20.2 %	6	$287 +9%
UBS	56 %	+11.5 %	9	$240 -9%
Morgan Stanley	55 %	+9.0 %	20	$200 -24%
Mizuho	58 %	+5.9 %	12	$230 -12%
JP Morgan	50 %	+4.8 %	8	$285 +9%
Barclays	50 %	+2.2 %	24	$210 -20%

In short — Should you invest in IQVIA? Is it too late, still worth it? Analysts are overwhelmingly positive (90% buy, median target $259, i.e. -1%), and the most reliable on IQV targets even higher. But the valuation is stretched (P/E ~33), it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

90% of analysts rate it a buy (Buy consensus, 10 ratings) — a sign of market conviction.
The most reliable firm on IQV, Baird (83% hit rate, 6 scored calls), targets $287 (call made on July 29, 2026, maturing on July 29, 2027) (+9%) in its most recent call, and $258 (call made on October 29, 2025, maturing on October 29, 2026) (-2%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 10 ratings, 1 is neutral.
Limited upside: the median target is only -1% from the current price.
High valuation (P/E ~33): strong growth is already "priced in", leaving little room for error.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on IQV

Median target $259 (-1%) · 10 ratings · Buy consensus

Strong Buy00%

Buy990%

Hold110%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in IQVIA now?

We won't decide for you. The facts: 90% of analysts rate it a buy, median target $259 (-1%), and Baird (most reliable on IQV, 83%) targets $287. Weigh that against valuation (P/E ~33). This is not personalized advice.

Is it too late to invest in IQVIA?

The stated upside is small: the median target ($259) sits just -1% from the price ($262) (most reliable on IQV: Baird, 83%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is IQVIA still worth investing in?

It depends on the gap between the price ($262) and its estimated value: analysts target $259 on median (-1%), with 90% buys (most reliable on IQV: Baird, 83%). Cross-check with their real reliability on IQV and the cautions above. Information, not advice.

What's the main risk in buying IQV?

The consensus is not unanimous: of 10 ratings, 1 is neutral.

→ Go deeper: the full IQVIA profile (consensus, analyst reliability, price target, performance).